Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults

Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults

IntroductionType 1 diabetes is characterized by pancreatic islet inflammation and autoimmune-driven pancreatic β-cell destruction. Interferon-α (IFNα) is a key player in early human type 1 diabetes pathogenesis. IFNα activates the tyrosine kinase 2 (TYK2)-signal transducer and activator of transcrip...

Full description

Bibliographic Details
Main Authors: Reinaldo S. Dos Santos, Daniel Guzman-Llorens, Atenea A. Perez-Serna, Angel Nadal, Laura Marroqui
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
apoptosis
deucravacitinib
inflammation
pancreatic β-cells
TYK2
type 1 diabetes
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1263926/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1263926/full

Similar Items